10-Q: Arbutus Biopharma Reports Q3 2024 Results, Focuses on HBV Pipeline

Arbutus Biopharma reported its Q3 2024 financial results, highlighting a strategic shift towards advancing its hepatitis B virus (HBV) pipeline and a restructuring to streamline operations.

Summary

• Arbutus Biopharma reported a net loss of $19.7 million for the third quarter of 2024, compared to a net loss of $20.1 million for the same period in 2023.
• The company's total revenue decreased to $1.3 million in Q3 2024 from $4.7 million in Q3 2023, primarily due to lower collaboration and license revenue.
• Operating expenses were $22.8 million in Q3 2024, which included a $3.6 million restructuring charge, compared to $26.2 million in Q3 2023.
• Research and development expenses decreased to $14.3 million in Q3 2024 from $20.2 million in Q3 2023, due to the discontinuation of certain programs.
• As of September 30, 2024, Arbutus had $130.8 million in cash, cash equivalents, and marketable securities.
• The company believes it has sufficient cash resources to fund operations into the fourth quarter of 2026.
• Arbutus implemented a 40% workforce reduction to focus on advancing its imdusiran and AB-101 programs.
• The company expects a net cash burn between $63 million and $67 million in 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a strong cash position and is focusing on its core programs, the restructuring, workforce reduction, and decreased revenue are concerning. The ongoing patent litigation also adds uncertainty.

Positives

• The company has a strong cash position of $130.8 million, which is expected to fund operations into the fourth quarter of 2026.
• Arbutus is focusing on its core HBV programs, which may lead to more efficient use of resources.
• Clinical data for imdusiran has shown promising results in reducing HBsAg and HBV DNA.
• The company has made progress in its patent litigation against Moderna, with a favorable claim construction ruling.
• The company has a collaboration with Qilu Pharmaceuticals for the development and commercialization of imdusiran in China.

Negatives

• The company experienced a decrease in revenue compared to the same period last year.
• The company incurred a net loss of $19.7 million for the quarter.
• The company has discontinued its IM-PROVE III clinical trial.
• The company has implemented a 40% workforce reduction.
• The company is involved in ongoing patent litigation, which can be costly and time-consuming.

Risks

• The company's success is dependent on obtaining regulatory approvals for its products.
• The company's research and development activities are subject to risks and uncertainties.
• The company's ability to fund its programs is dependent on obtaining adequate financing.
• The company is involved in ongoing patent litigation, which could have a material impact on its business.
• The company's future revenue is dependent on the success of its collaborations and licensing agreements.

Future Outlook

Arbutus believes its current cash resources are sufficient to fund operations into the fourth quarter of 2026. The company expects a net cash burn between $63 million and $67 million in 2024. They plan to focus on advancing their HBV pipeline, including imdusiran and AB-101.

Management Comments

• The company is streamlining the organization to focus on advancing the clinical development of imdusiran and AB-101.
• The company believes that a combination of compounds that can suppress HBV DNA replication and HBsAg expression as well as boost patients HBV-specific immune response could address the most important elements to achieving a functional cure.
• The company is positioning imdusiran as a potential cornerstone therapeutic in combination with AB-101 or other agents with potentially complementary mechanisms of action.

Industry Context

The focus on HBV therapeutics aligns with the growing need for effective treatments for chronic hepatitis B. The company's approach of combining different mechanisms of action, such as RNAi and immune modulation, reflects a trend in the industry towards combination therapies for complex diseases. The ongoing patent litigation highlights the competitive landscape and the importance of intellectual property in the biopharmaceutical sector.

Comparison to Industry Standards

• Arbutus's cash runway into Q4 2026 is relatively strong compared to many other clinical-stage biotech companies, which often have cash runways of 12-24 months.
• The company's focus on HBV is in line with the industry's increasing attention to liver diseases, with companies like Gilead Sciences and Vir Biotechnology also developing HBV therapies.
• The restructuring and workforce reduction are not uncommon in the biotech industry, especially for companies that are prioritizing specific programs and managing cash burn.
• The ongoing patent litigation is a common occurrence in the biopharmaceutical industry, with companies like Moderna and Pfizer also involved in similar disputes.
• The company's revenue is lower than some of its peers, but this is expected for a clinical-stage company that is not yet commercializing products.

Legal Proceedings

• Arbutus and Genevant are involved in ongoing patent litigation with Moderna and Pfizer/BioNTech regarding LNP technology.
• Acuitas filed a lawsuit against Arbutus and Genevant, which was later dismissed.
• Moderna filed a petition requesting the United States Patent and Trademark Office to institute an Inter Partes Review of Arbutus United States Patent 9,404,127.
• Moderna and Merck filed Notices of Opposition to Arbutus European patent EP 2279254.

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and net loss, but may be encouraged by the company's focus on its core programs and extended cash runway.
• Employees have been impacted by the 40% workforce reduction.
• Customers and partners may be affected by the company's strategic shift and discontinuation of certain programs.
• Creditors may be reassured by the company's strong cash position.

Next Steps

• The company will continue to advance its imdusiran and AB-101 programs.
• The company expects to report preliminary data from the AB-101 Phase 1a/1b clinical trial in the first half of 2025.
• The company intends to present additional follow-up data from the IM-PROVE I trial at the upcoming AASLD The Liver Meeting in November 2024.
• The company intends to present preliminary end-of-treatment data from the additional cohort of the IM-PROVE II trial at the upcoming AASLD The Liver Meeting in November 2024.
• The company will continue to pursue its patent litigation against Moderna and Pfizer/BioNTech.

Key Dates

Keywords

Hepatitis B, HBV, Imdusiran, AB-101, RNAi, PD-L1 inhibitor, Clinical trials, LNP technology, Patent litigation, Biopharmaceutical